ERBB2 and neoplasm: Some studies (Laurentpuig et al., 2016; Stahler et al., 2017) demonstrated patients with HER2 amplification tumor had a worse survival, but other studies (Pietrantonio et al., 2017; Richman et al., 2016) argued no meaningful relationships between this marker and survival.